{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:09:19Z","timestamp":1784750959912,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP240430"],"award-info":[{"award-number":["RP240430"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["2U54MD007605"],"award-info":[{"award-number":["2U54MD007605"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejps.2026.107585","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:17:08Z","timestamp":1781223428000},"page":"107585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The effect of pH stability and aqueous solubility on the oral bioavailability of a novel antileishmanial agent"],"prefix":"10.1016","volume":"224","author":[{"given":"Maria Rincon","family":"Nigro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolulope","family":"Adebusuyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manvir","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Olaleye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-8066","authenticated-orcid":false,"given":"Dong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107585_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/019262339502300203","article-title":"Basic principles of pharmacokinetics","volume":"23","author":"Benet","year":"1995","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejps.2026.107585_bib0014","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1742-7843.2009.00498.x","article-title":"Predicting drug disposition via application of a biopharmaceutics drug disposition classification system","volume":"106","author":"Benet","year":"2010","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"8","key":"10.1016\/j.ejps.2026.107585_bib0022","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.39.8.1671","article-title":"Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole","volume":"39","author":"Chin","year":"1995","journal-title":"Antimicrob. Agents Chemother"},{"issue":"6","key":"10.1016\/j.ejps.2026.107585_bib0024","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.addr.2007.09.009","article-title":"Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration","volume":"60","author":"Cole","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2026.107585_bib0013","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107585_bib0008","doi-asserted-by":"crossref","unstructured":"D.D. DePestel, P.H. Kazanjian, S.K. Cinti, C.A. Kauffman, P.L. Carver, Magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered didanosine tablets, Pharmacother.: J. Hum. Pharmacol. Drug Ther.. 24 (2004) 1539\u20131545. https:\/\/doi.org\/10.1592\/phco.24.16.1539.50959.","DOI":"10.1592\/phco.24.16.1539.50959"},{"key":"10.1016\/j.ejps.2026.107585_bib0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11095-016-2090-2","article-title":"Meal effects confound attempts to counteract rabeprazole-induced hypochlorhydria decreases in atazanavir absorption","volume":"34","author":"Faber","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107585_bib0002","doi-asserted-by":"crossref","unstructured":"Food, gastrointestinal pH, and models of oral drug absorption | Elsevier Enhanced Reader, (n.d.). https:\/\/doi.org\/10.1016\/j.ejpb.2016.11.034.","DOI":"10.1016\/j.ejpb.2016.11.034"},{"key":"10.1016\/j.ejps.2026.107585_bib0027","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fphar.2019.00459","article-title":"Evaluation of self-nanemulsifying drug delivery systems (SNEDDS) for poorly water-soluble talinolol: Preparation, in vitro and in vivo assessment","volume":"10","author":"Kazi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107585_bib0017","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1002\/jps.24401","article-title":"Evaluation of acid tolerance of drugs using rats and dogs controlled for gastric acid secretion","volume":"104","author":"Kosugi","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.ejps.2026.107585_bib0023","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/00003088-200544100-00003","article-title":"Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir","volume":"44","author":"Le Tiec","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2026.107585_bib0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.60.1.0008","article-title":"Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments","volume":"60","author":"McConnell","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107585_bib0019","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1021\/mp400256h","article-title":"Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development","volume":"10","author":"Mitra","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107585_bib0018","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00228-005-0077-8","article-title":"Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes","volume":"62","author":"Miura","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107585_bib0003","unstructured":"Oral Drug Absorption: Prediction and Assessment, (n.d.). https:\/\/web.p.ebscohost.com\/ehost\/ebookviewer\/ebook\/bmxlYmtfXzQ0ODI0\u00d719BTg2?sid=ef9ba4cb-63e0-4b20-8594-9ddacfdb3c87@redis&vid=0&format=EB&rid=1 (accessed April 28, 2022)."},{"key":"10.1016\/j.ejps.2026.107585_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/00365528509095824","article-title":"Development of an oral formulation of omeprazole","volume":"20","author":"Pilbrant","year":"1985","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2026.107585_bib0005","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejps.2026.107585_bib0028","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107585_bib0012","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.3390\/ijerph18094624","article-title":"Development and validation of a sensitive, specific and reproducible UPLC-MS\/MS method for the quantification of OJT007, a novel anti-leishmanial agent: application to a pharmacokinetic study","volume":"18","author":"Rincon Nigro","year":"2021","journal-title":"Int. J. Env. Res. Public Health"},{"key":"10.1016\/j.ejps.2026.107585_bib0011","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/molecules27092854","article-title":"Metabolite identification of a novel anti-leishmanial agent OJT007 in rat liver microsomes using LC-MS\/MS","volume":"27","author":"Rincon Nigro","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.ejps.2026.107585_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01422-19","article-title":"Vitro and In Vivo characterization of potent antileishmanial methionine aminopeptidase-1 inhibitors","author":"Rodriguez","year":"2020","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejps.2026.107585_bib0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jps.2600610111","article-title":"Influence of route of administration on drug availability","volume":"61","author":"Rowland","year":"1972","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107585_bib0001","article-title":"Drug Solubility: Importance and Enhancement Techniques","volume":"2012","author":"Savjani","year":"2012","journal-title":"ISRN. Pharm."},{"issue":"7","key":"10.1016\/j.ejps.2026.107585_bib0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2007.05.010","article-title":"Salt formation to improve drug solubility","volume":"59","author":"Serajuddin","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2026.107585_bib0009","first-page":"8","article-title":"A new model for the population pharmacokinetics of didanosine in healthy subjects","author":"Velasque","year":"2007","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"3 Pt B","key":"10.1016\/j.ejps.2026.107585_bib0026","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ejpb.2013.09.007","article-title":"Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs","volume":"85","author":"Vo","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2026.107585_bib0004","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11095-004-1185-3","article-title":"pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model","volume":"22","author":"Zhou","year":"2005","journal-title":"Pharm. Res."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:23:36Z","timestamp":1784748216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S0928098726001594"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107585","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of pH stability and aqueous solubility on the oral bioavailability of a novel antileishmanial agent","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107585"}}